CGON

CG Oncology, Inc. is a clinical-stage biopharmaceutical company focused on developing oncolytic immunotherapies for bladder cancer and other urologic cancers. The company's lead product candidate is an oncolytic adenovirus designed to selectively infect and replicate in cancer cells, destroying the tumor while stimulating an anti-tumor immune response. CG Oncology is advancing this therapy through clinical trials for non-muscle invasive bladder cancer, a significant unmet medical need where treatment options remain limited and recurrence rates are high. The company's approach combines the direct oncolytic effect of viral tumor destruction with immune system activation to target residual cancer cells. CG Oncology focuses on urologic cancers where localized delivery of oncolytic immunotherapy may provide therapeutic benefits while minimizing systemic side effects. The company collaborates with research institutions and medical centers to conduct clinical trials and advance its pipeline. As a clinical-stage company, CG Oncology does not yet generate product revenue and is focused on clinical development and regulatory advancement of its therapeutic candidates.